Disease-Focused Discovery

PureTech established the underlying programs and platforms that resulted in 26 therapeutics and therapeutic candidates that are being advanced within PureTech's Wholly Owned Pipeline or by its Founded Entities, including two products that have been cleared for marketing by the FDA and granted marketing authorization in the European Economic Area.

View our corporate deck.

PureTech's Components of Value

Wholly Owned Pipeline

Our programs1
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
IPF & potentially other PF-ILDs

2

IPF & potentially other progressive fibrosing ILDs

~200K U.S. (PF-ILDs, including IPF) 


Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., idiopathic pulmonary fibrosis (IPF) and potentially other progressive fibrosing interstitial lung diseases (PF-ILDs) and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema.

LYT-100
Deupirfenidone
Long COVID2 respiratory complications & related sequelae

2

Long COVID respiratory complications & related sequelae

>150M Worldwide

Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., idiopathic pulmonary fibrosis (IPF) and potentially other progressive fibrosing interstitial lung diseases (PF-ILDs) and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema.
LYT-100
Deupirfenidone
Lymphatic flow disorders, including lymphedema

2a

Lymphatic flow disorders, incl. lymphedema

~1M U.S.

Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., idiopathic pulmonary fibrosis (IPF) and potentially other progressive fibrosing interstitial lung diseases (PF-ILDs) and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema.
LYT-200
Anti-Galectin-9 MAb
Solid tumors

1

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


Fully human monoclonal antibody designed to inhibit the activity of galectin-9, a key molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells, which we are developing for difficult-to-treat cancer indications with poor survival rates, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA).

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

>50K/year U.S. (Metastatic CRC)
>28K/year U.S. (Metastatic pancreatic cancer)
>4K/year U.S. (Metastatic cholangiocarcinoma)


Fully human IgG1 monoclonal antibody directed against the delta-1 chain of T cells bearing gamma delta-1 T cell receptors that we have designed to target and deplete immunosuppressive gamma delta-1 T cells in cancer.

LYT-300
Oral Allopregnanolone
Neurological indications

Preclinical

Neurological indications

Oral form of allopregnanolone, a natural neurosteroid, that we believe may be applicable to a range of neurological conditions. An IV version of allopregnanolone, also known as brexanolone, is approved by the FDA to treat postpartum depression.
Phase completedPhase in progressRegistration-enabling studies planned

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.
2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS). 

Founded Entities

$1.2B


Investments and Non-Dilutive Funding Raised by Founded Entities Since January 20173

Controlling Interest or Right to Receive Royalties

Advancing a novel hydrogel platform technology to treat obesity and other chronic metabolic diseases

19.3% Equity plus Royalties
COMMERCIAL LAUNCH
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
Plenity®4,5

Weight management

~150M U.S. (Overweight and obesity)

Commercial Launch
Therapeutic Candidate:
GS1004

Adolescent weight management

~13.7M U.S.

Preclinical4
Therapeutic Candidate:
GS2004

Weight management in type 2 diabetes (T2D)/prediabetes

~32M U.S. (T2D)
~88M U.S. (Prediabetes)

Phase 2
Therapeutic Candidate:
GS3004

Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease

~80-100M U.S.

Phase 2 Ready4
Therapeutic Candidate:
GS5004

Functional constipation

~35M U.S.

Phase 3

Advancing transformative medicines for people living with psychiatric and neurological conditions

8.2% Equity plus Royalties
PHASE 3
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
KarXT

Schizophrenia

~2.7M U.S.

Phase 3
Dementia-related psychosis
~1.2M U.S.
Phase 1b

Building a regenerative biology platform for androgenetic alopecia, epithelial aging and other medical indications

78.2% Equity plus Royalties
PHASE 3 READY
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
FOL-004

Androgenetic alopecia

~90M U.S.

Phase 3 Ready
Pioneering a new category of therapies for immune-mediated diseases
49.5% Equity
PHASE 2
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
VE303

High-risk Clostridioides difficile

~100-120K/year U.S.

Phase 2
Therapeutic Candidate:
VE416

Food allergy

~2.5M U.S. (Peanut allergy)

Phase 1/2
Therapeutic Candidate:
VE202

Inflammatory bowel disease

~3M U.S.

Phase 2 Ready
Therapeutic Candidate:
VE800

Solid tumors

>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)

Phase 1
Developing a voice-based technology platform to measure health when a person speaks
44.6% Equity
COMMERCIAL RELEASE
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
Sonde One for Respiratory4
Respiratory risk detection and monitoring app
Commercial Release
Therapeutic Candidate:
Sonde One for Mental Fitness4

Depressive symptoms detection and monitoring app

~17M U.S.

Product and Clinical Validation
Pioneering inflammation targeted disease immunomodulation
78.0% Equity
PRECLINICAL
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
ALV-107
Interstitial cystitis/Bladder pain syndrome
~4-12M U.S.
Preclinical
Therapeutic Candidate:
ALV-304
Inflammatory bowel disease
~3M U.S.
Preclinical
Therapeutic Candidate:
ALV-306
Chronic pouchitis
~20K-44K U.S.
Preclinical
Engineering hydrogels to enable the oral administration of biologics
72.9% Equity
CONTINUED ADVANCEMENT OF THE PLATFORM

Equity Interest Only

Advancing digital treatments to target cognitive dysfunction associated with conditions across neurology and psychiatry
33.7% Equity
COMMERCIAL LAUNCH
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
EndeavorRx™7 (AKL-T01)

ADHD

~6.4M U.S. (Pediatric ADHD)

Scaled commercial launch
Therapeutic Candidate:
Cognitive dysfunction in depression

Major depressive disorder

Discovery and research
Therapeutic Candidate:
Cognitive dysfunction in multiple sclerosis

Multiple sclerosis

Discovery and research
Therapeutic Candidate:
Autism spectrum disorder

Autism spectrum disorder

Discovery and research
Therapeutic Candidate:
Post-COVID cognitive dysfunction

COVID brain fog

Discovery and research
Engineering hematopoietic stem cell therapies combined with targeted therapies
8.6% Equity
PHASE 1/2
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
VOR33 (CD33)
Acute myeloid leukemia
~42,500/year U.S., Europe, Japan
Phase 1/2A Ready
Myelodysplastic syndromes, myeloproliferative neoplasms
Preclinical
Therapeutic Candidate:
VCAR33
Bridge-to-transplant AML
Phase 1/2

Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representationto the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of December 31, 2020, Controlled Founded Entities include Follica Incorporated, Vedanta Biosciences, Inc., Sonde Health, Inc., Alivio Therapeutics, Inc. and Entrega, Inc., and Non-Controlled Founded Entities include Gelesis, Inc., Karuna Therapeutics, Inc., Akili Interactive Labs, Inc., Vor Biopharma Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2020, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Karuna ownership and Vor ownership were calculated on an outstanding voting share basis as of April 30, 2021. With the exception of Plenity and EndeavorRx, candidates are investigational and have not been cleared by the FDA for use in the United States. 
3 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations such as those with Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Funding figure does not include Vor’s gross proceeds of $203.4 million from its February 2021 post-period IPO or Karuna’s gross proceeds of $269.8 million from its February 2021 post-period follow-on offering. Calculated as of January 1, 2017 to December 31, 2020. 
4 These therapeutic candidates are regulated as devices and their development has been approximately equated to phases of clinical development.
5 Important Safety Information: Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity. To avoid impact on the absorption of medications: For all medications that should be taken with food, take them after starting a meal. For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician. The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor. Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.
6 Contingent on FDA review of the research plan.
7 EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. 

Cash at Parent Level

$443.4M


PureTech Level Cash and Cash Equivalents as of March 31, 20218

8 This represents a non-IFRS number.  For a reconciliation of this number to IFRS, please see below:

 

 

 

 

 

 

Consolidated Cash Reserves is a non IFRS-measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and consolidated subsidiaries. PureTech Level Cash Reserves is a non-IFRS measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and only wholly-owned subsidiaries. PureTech Level Cash and Cash Equivalents is a non-IFRS measure which consists of cash and cash equivalents held at PureTech Health plc and only wholly-owned subsidiaries. 

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with several pharma companies or their investment arms